Jump to section
To improve the world's most important health decisions.
8% employee growth in 12 months
Pattern Bioscience aims to make a significant impact in the battle against antibiotic-resistant infections, which have long been recognized as detrimental to our health and a major financial burden on the healthcare system.
It uses single-cell technology, eliminating the need for time-consuming bacterial cultures. This approach provides healthcare professionals with rapid and accurate information, enabling them to promptly prescribe the most effective antibiotics for their patients.
With investments from multiple organizations, Pattern Bioscience has been able to successfully develop its infectious disease diagnostic platform. While its initial focus was on pneumonia testing, the company achieved a significant milestone in 2021 when the FDA granted it breakthrough status. Currently, it is expanding its platform capabilities to enable a range of infectious disease tests in order to enhance its ability to address diverse medical challenges.
Freddie
Company Specialist at Welcome to the Jungle
Apr 2023
$28.7m
SERIES C
Jul 2020
$9m
SERIES B
Nicolas Arab
(CEO & Co-Founder)Previously worked at Luminex in various roles, including Electrical Engineering Manager and Senior Director of Advanced Technology.
Ross Johnson
(Co-Founder)Graduated from the University of Texas with an Masters in Mechanical Engineering. Previously worked at Luminex as a Mechanical Engineer.